FDBusiness.com

Nestlé Health Science to Develop New Therapy to Treat Ulcerative Colitis

 Breaking News
  • Autumn Chill Puts Sunday Lunch Back on the Menu For UK Shoppers UK shoppers have returned to seasonal favourites as supermarket spending cools off, according to the latest figures from Kantar Worldpanel, for the 12 weeks to 7 October 2018. Overall sales grew 3.2% compared to the same 12 weeks last year. Though this is a slight slowdown from the highs reached during 2018’s hot summer, sales [...]...
  • Müller Milk & Ingredients Completes Integration and Appoints CFO Brian Watson has been appointed as Chief Finance Officer at Müller Milk & Ingredients (MMI). He joins the business from Marmon, a $7.7 billion Berkshire Hathaway company operating in the supermarket and food service sector. The appointment comes as MMI confirms completion of the biggest integration the UK dairy industry has ever seen – merging [...]...
  • Emmi Leads by Example As a manufacturer of speciality cheeses, Swiss dairy group Emmi is now setting an example for environmental protection by investing in a high-performance photovoltaic system at its Platteville site in the state of Wisconsin in the US. With 1,600 panels installed on the roof, the system can cover 15% of the company’s electricity requirement. The [...]...
  • Kerry Group Commits €1 Million to Bring RAIN Programme to West Africa Kerry Group has extended its partnership with Concern Worldwide through a 4-year project to improve food security and nutrition in Niger. The Realigning Agriculture to Improve Nutrition (RAIN) programme will make lasting improvements to food security, nutrition and the overall livelihoods in the Tahoua Region of Niger. This second phase of the RAIN programme will [...]...
  • Greencore to Divest US Business in $1 Billion Deal Greencore Group, the Irish and UK convenience food business, has agreed to sell its entire US business to an affiliate of Hearthside Food Solutions for US$1.075 billion (£817 million) on a cash and debt-free basis. Hearthside is a major US contract food manufacturer with a heritage in US food industry outsourcing. The disposal will leave [...]...

Nestlé Health Science to Develop New Therapy to Treat Ulcerative Colitis

Nestlé Health Science to Develop New Therapy to Treat Ulcerative Colitis
September 22
10:00 2015

Nestlé Health Science has entered into a license agreement with Lipid Therapeutics for exclusive rights worldwide, except for Europe and Australia, to Lipid Therapeutics’ LT-02 compound (phosphatidylcholine), a novel barrier function therapy for patients with mild-to-moderate ulcerative colitis. Under this agreement, Nestlé Health Science will further develop and commercialize LT-02 upon marketing approval by the relevant authorities in the licensed geographies. Nestlé Health Science plans to start phase III clinical trials in the US in 2016. The financial terms of the licensing partnership are not being disclosed.

Lipid Therapeutics’ European development partner, Dr Falk Pharma GmbH, a pharmaceutical company specialized in gastroenterology, announced the start of phase III trials for LT-02 in Europe in October 2014. As part of a strategic development approach, Nestlé Health Science, Dr Falk and Lipid Therapeutics will collaborate to generate the required clinical evidence in support of LT-02’s beneficial effects in the treatment of ulcerative colitis in order to obtain drug regulatory approvals.

More than one million people worldwide are estimated to suffer from ulcerative colitis, a chronic and debilitating inflammatory condition of the large intestine. The most common treatment is 5-aminosalicylic acid (mesalazine), However it is estimated that 40% of patients receiving the recommended dose of 5-aminosalicylic acid continue to experience persistent disease activity flares. The NHSc development program will primarily assess LT-02 as an add-on therapy to 5-aminosalicylic acid. LT-02 has a novel mode of action that restores the colonic barrier function in the gut mucosa or ‘wall’ and through anti-inflammatory signalling and represents a first-in-class therapy for those patients still suffering flares while being treated with mesalazine.

Greg Behar CEO of Nestlé Health Science, says: “LT-02 has paradigm changing potential in the management of ulcerative colitis in terms of improving patient outcomes and reducing the need for biologics and corticosteroids. The growing number of patients that suffer from chronic gastrointestinal conditions worldwide increases our determination to make an impact, through innovative, integrated therapeutic approaches. This agreement enables us to further build our gastrointestinal pipeline, a key focus of our Novel Therapeutic Nutrition business area with the aim of developing nutritional therapies coupled with innovative drug and diagnostics solutions.”

Dr Gerhard Keilhauer, CEO of Lipid Therapeutics, says: “Based upon initial trials, we are convinced of the transformational potential of LT-02. With Dr Falk Pharma and now Nestlé Health Science as licensees in key geographies, the resources and capabilities are at work to translate potential into a breakthrough therapy.”

This licensing agreement is part of Nestlé Health Science’s strategy to develop its product portfolio for gastrointestinal diseases, a key focus of its Novel Therapeutic Nutrition business area.

About Author

mike

mike

Related Articles



Food & Drink Business Conference & Exhibition 2016

Upcoming Events

  • October 18, 2018Future Food-Tech London - Marketing Partnership
  • October 21, 2018Int'l Food Products Exhibition (Sial)
  • October 25, 2018Italian Espresso Coffee Show (TriestEspresso Expo)
  • October 25, 2018Finnish Food Fair
AEC v1.0.4

find food jobs

The Magazine

F&D Business Preferred Suppliers

New Subscriber





Subscribe Here



Advertisements